uniQure Q1 2021 Earnings Report
Key Takeaways
uniQure reported its financial results for the first quarter of 2021. The company held cash and cash equivalents of $260.8 million as of March 31, 2021. Revenue for the quarter was $0.5 million, and the net loss was $41.6 million, or $0.91 loss per share.
52-week follow-up data from HOPE-B pivotal study expected to be presented later this quarter.
Announced closing of the global commercialization and license agreement with CSL Behring for hemophilia B gene therapy.
Completed enrollment of first dose cohort of U.S. Phase I/II clinical trial of AMT-130 for Huntington’s disease, with initiation of second dose cohort and European Phase Ib/II expected in second half of 2021.
Pierre Caloz to be appointed Chief Operating Officer.
uniQure
uniQure
Forward Guidance
uniQure expects to announce top-line, 52-week follow-up data from the HOPE-B pivotal trial, initiate collaboration with CSL Behring, hold an R&D Day, begin patient enrollment in the second cohort of AMT-130, initiate an open-label European study of AMT-130, submit the BLA for etranacogene dezaparvovec and announce early data on the first four patients in the Phase I/II study of AMT-130.